Lv4
488 积分 2024-05-24 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
5天前
已完结
[Quality control index for standardized diagnosis and treatment of nasopharyngeal carcinoma in China (2022 edition)]
8天前
已完结
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
16天前
已完结
Mitochondrial-derived peptides, HNG and SHLP3, protect cochlear hair cells against gentamicin
25天前
已完结
Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial
2个月前
已完结
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
3个月前
已完结
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
3个月前
已完结
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
3个月前
已完结
Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy
3个月前
已完结
Immunotherapeutics in nasopharyngeal carcinoma: a relentless CONTINUUM of success
3个月前
已完结
皖公网安备34019202002308
